Linked Life Data

17533126

Source:http://linkedlifedata.com/resource/pubmed/id/17533126

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17533126rdf:typepubmed:Citationlld:pubmed
pubmed-article:17533126lifeskim:mentionsumls-concept:C0040682lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C0332285lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C1420841lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C2698300lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:17533126lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:17533126pubmed:issue15lld:pubmed
pubmed-article:17533126pubmed:dateCreated2007-7-10lld:pubmed
pubmed-article:17533126pubmed:abstractTextUtilization of N-substituted-4-hydroxy-3-methylsulfonanilidoethanolamines 1 as selective beta(3) agonists is complicated by their propensity to undergo metabolic oxidative N-dealkylation, generating 0.01-2% of a very potent alpha(1) adrenergic agonist 2. A summary of the SAR for this hepatic microsomal conversion precedes presentation of strategies to maintain the advantages of chemotype 1 while mitigating the consequences of N-dealkylation. This effort led to the identification of 4-hydroxy-3-methylsulfonanilidopropanolamines 15 for which the SAR for the unique stereochemical requirements for binding to the beta adrenergic receptors culminated in the identification of the potent, selective beta(3) agonist 15f.lld:pubmed
pubmed-article:17533126pubmed:languageenglld:pubmed
pubmed-article:17533126pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17533126pubmed:citationSubsetIMlld:pubmed
pubmed-article:17533126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17533126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17533126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17533126pubmed:statusMEDLINElld:pubmed
pubmed-article:17533126pubmed:monthAuglld:pubmed
pubmed-article:17533126pubmed:issn0960-894Xlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:ShawKKlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:RussellA DADlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:AhmedSSlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:GeorgeR JRJlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:Abboa-OffeiB...lld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:WaldronT LTLlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:SeymourA AAAlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:DejnekaTTlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:WuGGlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:McCannPPlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:ZhangMMlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:CatIIlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:GodfreyJ DJDlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:ZhangHHlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:TesfamariamBBlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:DickinsonK...lld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:FrohlichB HBHlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:AllenG TGTlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:SlusarchykD...lld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:WashburnW NWNlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:MikkilineniAAlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:SkwishSSlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:HarperT WTWlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:GavamMMlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:SherP MPMlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:HangelandJJlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:GirotraRRlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:CaringalYYlld:pubmed
pubmed-article:17533126pubmed:authorpubmed-author:ChengP T WPTlld:pubmed
pubmed-article:17533126pubmed:issnTypePrintlld:pubmed
pubmed-article:17533126pubmed:day1lld:pubmed
pubmed-article:17533126pubmed:volume17lld:pubmed
pubmed-article:17533126pubmed:ownerNLMlld:pubmed
pubmed-article:17533126pubmed:authorsCompleteYlld:pubmed
pubmed-article:17533126pubmed:pagination4290-6lld:pubmed
pubmed-article:17533126pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:meshHeadingpubmed-meshheading:17533126...lld:pubmed
pubmed-article:17533126pubmed:year2007lld:pubmed
pubmed-article:17533126pubmed:articleTitleArylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.lld:pubmed
pubmed-article:17533126pubmed:affiliationBristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA. William.Washburn@bms.comlld:pubmed
pubmed-article:17533126pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17533126lld:chembl